Report error Found 280 with Last Name = 'schmelzle' and Initial = 't'
TargetTranscriptional enhancer factor TEF-3(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataKd: 25nMAssay Description:Binding affinity to Avi-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) by SPR assayMore data for this Ligand-Target Pair
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.5nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
